

Commentary: Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis

Jun Sun

Department of Medicine, University of Illinois at Chicago 840 S Wood Street, Room 704 CSB, MC716, USA

Article Info

Article Notes

Received: May 19, 2017

Accepted: June 12, 2017

*Correspondence:

Associate Professor

Division of Gastroenterology and Hepatology

Department of Medicine, University of Illinois at Chicago, 840 S

Wood Street, Room 704 CSB, MC716, USA

Tel: 312-996-5020, Email: junsun7@uic.edu

© 2017 Sun J. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a neuromuscular disease characterized by a progressive death of motor neurons and muscle atrophy. Most ALS patients die within 5 years of disease onset. Currently, treatment with the US Food and Drug Administration (FDA) approved drug, Riluzole, merely extends the patient's life span for a few months. For the second time in history, FDA has approved a new drug edaravone specifically for the treatment of ALS in May 8, 2017. There is still a need to develop new treatments for alleviating the disease progression and improving the lives of ALS patients.

The gut is considered the second brain of the human being. It contains roughly the same amount of neurons as the spinal cord. The integrative function of gut-secreted hormones plays an important role in human physiology and pathophysiology. Emerging evidence has shown that altered intestinal homeostasis and microbiome contribute to a variety of neurological diseases, including autism and Parkinson's disease¹⁻³. However, very little is known about the roles of intestine and microbiome in ALS. Our lab is the first to discover the link between intestinal homeostasis and the disease progression in an ALS mouse model G93A^{4,5}.

Our recent study, entitled "*Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis*", has revealed a promising link of dysbiosis and aberrant intestine to disease progression in an ALS mouse model with overexpression of human mutation gene superoxide dismutase 1 (*SOD1*^{G93A})⁴. Mouse models expressing ALS-linked *SOD1* mutations (e.g. *SOD1*^{G93A}) effectively recapitulate many features of the human disease, and have been extensively used to investigate pathogenic mechanisms of ALS⁶. The *SOD1*^{G93A} mice show dysbiosis with reduced butyrate-producing bacteria⁵. These changes occur in young G93A mice before ALS onset. In the current study, we hypothesize that restoring microbiome and intestinal homeostasis delays disease onset and progression of ALS. After being fed with the beneficial bacteria product butyrate, G93A mice exhibited a delay in the onset of ALS symptoms and a prolonged life span.

Bacterial products short chain fatty acids (SCFA) provide energy for the colonocytes and exert beneficial effects in the gut⁷. Butyrate (a SCFA) and butyrate-producing bacteria are thought to have beneficial effects to the host through anti-inflammatory properties⁸. In our study, treatment with butyrate delays disease onset in the *SOD1*^{G93A} mouse. Butyrate synthesis by anaerobic bacteria can occur via butyryl-coenzyme A (CoA): acetate CoA-transferase⁹. In our study, oral 2% sodium butyrate treatment for 2.5 months restores the physiological CoA enzyme levels (comparable to wild

type mice) in pre-symptomatic SOD1 mice. Interestingly, our unpublished data also show that ALS patients had significantly low butyrate and total SCFA levels.

Intestinal epithelia of SOD1^{G93A} mice have a disrupted tight junction structure accompanied with increased intestinal permeability^{4,5}. Paneth cells are specialized intestinal epithelial cells that regulate the host-bacterial interactions in gut^{10,11}. The abnormal Paneth cells were significantly increased in the SOD1^{G93A} mice. We found that butyrate, restored some of the intestinal defects and corrected dysbiosis in the ALS mice. At the cellular level, butyrate treatment decreased abnormal Paneth cells. Moreover, butyrate reduced aggregation of the G93A-SOD1 mutated protein in small intestine and colon of ALS mice.

Based on the current data, the improvements due to pre-symptomatic butyrate treatment include improving the intestinal barriers, correcting dysbiosis, restoring Paneth cells, and reducing aggregation of the G93A-SOD1 mutated protein in ALS mice, thus slowing down the progression of disease. This study focuses on investigating the novel role of gut microbiome and intestinal functions in ALS and exploring potential therapeutic targets for ALS by restoring healthy host-bacterial interactions. It highlights the complex roles of microbial and intestinal homeostasis that contribute to the neuromuscular dysfunction in ALS. It has provided insight into targeting intestinal functions and microbiome that may slow down ALS pathogenesis.

Sodium phenylbutyrate has been widely considered as an inhibitor of histone deacetylases (HDAC)^{12,13}. It is used in the ALS mice through intraperitoneal injection¹⁴ and tested in ALS patients for safety¹⁵. Sodium phenylbutyrate can contribute to gut function through modulation of tight junctions¹⁶. Therefore, the proactive role of sodium phenylbutyrate in ALS could also through restoring intestinal permeability. Understanding the molecular mechanism for the direct beneficial roles of butyrate on neuromuscular dysfunction in ALS is an ongoing study in our research team. A HDAC inhibitor could be used as a control for its effects on intestinal microbiome.

Most ALS cases are sporadic (SALS), with about 10% being familial (FALS). Both SALS and FALS manifest similar pathological and clinical phenotypes, suggesting that different initiating causes lead to a mechanistically similar neurodegenerative pathway. A fraction of FALS are associated with mutations in the superoxide dismutase gene *SOD1*¹⁷. It may be interesting to evaluate other ALS experimental models, i.e. transactive response DNA binding protein (TDP)-43 mouse model).

In SALS, there is study reported the increased circulating bacterial lipopolysaccharides (LPS) and systemic immune activation¹⁸. Our unpublished data evaluates the gastrointestinal health and microbiome

profile of patients with heterogenous motor neuron syndromes. We observed decreased diversity, altered ratio of two major bacterial members: *Firmicutes* and *Bacteroidetes*, and low butyrate in human ALS. Only one patient did not have a low *Firmicutes* / *Bacteroidetes* ratio. Further, our unpublished study has shown elevated intestinal inflammation in ALS patients. Along these lines, ALS G93A mice showed abnormal intestinal microbiome, in which butyrate-producing bacteria (*Butyrivibrio Fibrisolvens*) were reduced. *Firmicutes* make up the largest portion of the mouse and human gut microbiome¹⁹. The division *Firmicutes* as part of the gut flora has been shown to be involved in energy resorption and obesity^{20,21}. *Firmicutes Peptostreptococcus*, which was low in ALS mice⁵, was also enhanced after butyrate treatment. Several clinical studies have demonstrated the safety for butyrate or its derivative in human subjects²². Thus, our study with oral sodium butyrate treatment in the G93A mice may be applied to both SALS and FALS for translation to clinical therapy.

Humans have coevolved with their microbes over thousands of years, but this relationship, is now being dramatically affected by shifts in the collective human microbiome resulting from changes in the environment and societal norms²³. Mismatches in host-microbe relationships lead to homeostatic chaos, likely explaining the increased incidence and prevalence of many disorders that have merged with alarming frequency in the modern age. We still lack research on the early intestinal issue from ALS patients. ALS research need learn from the experience and lessons in the field of inflammatory bowel diseases, obesity, and other chronic diseases. A better understanding of human microbiome would facilitate the development of targeted interventions to control the progression of ALS.

Acknowledgement

We would like to acknowledge the NIDDK/National Institutes of Health grant R01 DK105118 to Jun Sun.

References

1. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell*. 2013; 155: 1451-63.
2. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. *PLoS One*. 2011; 6: e28032.
3. Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell*. 2016; 167: 1469-1480 e12.
4. Zhang YG, Wu S, Yi J, et al. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. *Clin Ther*. 2017; 39: 322-336.
5. Wu S, Yi J, Zhang YG, et al. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. *Physiological reports*. 2015; 3.

6. McGoldrick P, Joyce PI, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. *Biochim Biophys Acta*. 2013; 1832: 1421-36.
7. Wu S, Yi J, Zhang YG, et al. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. *Physiol Rep*. 2015; 3.
8. Wu S, Zhang YG, Lu R, et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. *Gut*. 2015; 64: 1082-94.
9. Duncan SH, Barcenilla A, Stewart CS, et al. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. *Appl Environ Microbiol*. 2002; 68: 5186-90.
10. Sun J. Vitamin D receptor regulates autophagic activity through ATG16L1. *Autophagy*. 2016;12:1057-8.
11. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. *Nature*. 2008; 456: 259-63.
12. Davie JR. Inhibition of histone deacetylase activity by butyrate. *The Journal of nutrition*. 2003; 133: 2485S-2493S.
13. Cuadrado Tejedor M, Ricobaraza AL, Torrijo R, et al. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer's disease-like phenotype of a commonly used mouse model. *Current pharmaceutical design*. 2013; 19: 5076-84.
14. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. *J Neurochem*. 2005; 93: 1087-98.
15. Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. *Amyotroph Lateral Scler*. 2009; 10: 99-106.
16. Bordin M, D'Atri F, Guillemot L, et al. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. *Mol Cancer Res*. 2004; 2: 692-701.
17. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nat Rev Neurosci*. 2006; 7: 710-23.
18. Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). *J Neuroimmunol*, 2009; 206: 121-4.
19. Ley RE, Peterson DA, Gordon JL. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell*. 2006; 124: 837-48.
20. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. *Nature*. 2006; 444: 1022-3.
21. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A*. 2005; 102: 11070-5.
22. Vernia P, Monteleone G, Grandinetti G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. *Digestive diseases and sciences*. 2000; 45: 976-81.
23. Sun J, Chang EB. Exploring gut microbes in human health and disease: Pushing the envelope. *Genes Dis*. 2014; 1: 132-139.